AstraZeneca PLC
LSE:AZN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
AstraZeneca PLC
LSE:AZN
|
UK |
|
M
|
MaxCyte Inc
NASDAQ:MXCT
|
US |
|
C
|
Cronos Group Inc
F:7CI
|
CA |
|
A
|
Axalta Coating Systems Ltd
F:9AX
|
BM |
|
R
|
Robert Half Inc
SWB:RHJ
|
US |
|
Aeroflot-Rossiyskiye Avialinii PAO
MOEX:AFLT
|
RU |
|
Multipolar Tbk PT
IDX:MLPL
|
ID |
|
S
|
Sherwin-Williams Co
F:SJ3
|
US |
Intrinsic Value
Is AZN undervalued or overvalued?
See the intrinsic value estimate for AstraZeneca PLC and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What AstraZeneca Does
AstraZeneca is a global pharmaceutical company that discovers, develops, and sells prescription medicines. Its drugs treat major illnesses such as cancer, heart and kidney disease, respiratory conditions, and rare diseases. The company works with doctors, hospitals, and health systems, and it earns money mainly by selling patented medicines and, in some cases, by licensing or partnering on drug programs.
- Headquarters
- United Kingdom UK
- Employees
- 96 100
- IPO date
- Sep 21, 2007
AstraZeneca has a wide economic moat
Patents and exclusive rights to sell approved medicines prevent rivals from offering cheaper copies of AstraZeneca’s protected treatments. Its range of protected drugs and continuing development of new medicines spread that protection across several diseases rather than relying on a single product.
Read the full moat analysis
Revenue & Expenses Breakdown
AstraZeneca PLC
Earnings Waterfall
AstraZeneca PLC
The intrinsic value for AstraZeneca PLC (AZN) under the Base Case is hidden GBX.
Compared with the current market price of 13 814 GBX, the stock appears hidden.